Results for the secondary and tertiary endpoints of the IMPROVE study will be available at the end of the 40-week treatment period.
The safety profile of the new formulation of Rebif(R) reported in this study is consistent with the known safety profile of Rebif(R). No unexpected safety concerns were identified in this study.
The new formulation of Rebif(R) was approved in the European Union in August 2007 and in Canada in September 2007. It is now marketed in all EU countries and in Canada. The new formulation of Rebif(R) is not available in the United States.
Rebif(R) (interferon beta-1a) is a disease-modifying drug used to treat relapsing forms of multiple sclerosis (MS) and is similar to the interferon beta protein produced by the human body. The efficacy of Rebif(R) in chronic progressive MS has not been established. Interferons are thought to help modulate the body's immune system and reduce inflammation. The exact mechanism is unknown.
Rebif(R), which was approved in Europe in 1998 and in the US in 2002, is registered in more than 80 countries worldwide. Rebif(R) has been proven to delay the progression of disability, reduce the frequency of relapses and reduce MRI lesion activity and area.* Rebif(R) is available in a 22 micrograms and 44 micrograms ready-to-use pre-filled syringe and a titration pack (8.8 micrograms).
Rebif(R) should be used with caution in patients with a history of
depression, liver disease and seizures. Most commonly reported side effects
are flu-like symptoms, injection site disorders, elevation of liver enzymes
and blood cell abnormalities. Patients, especially those with depression,
seizure disorders, or liver problems, should discuss treatment with
Rebif(R) with their doctors. For more information about Rebif(R), please
|SOURCE Merck Serono|
Copyright©2008 PR Newswire.
All rights reserved